^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Adenosine A2B receptor antagonist

    Related drugs:
    Apply
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485)
    Phase 1
    Incyte Corporation
    Completed
    Last update posted :
    02/18/2025
    Initiation :
    02/03/2021
    Primary completion :
    01/22/2024
    Completion :
    01/22/2024
    CD8
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma (NCT05335941)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/13/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    MTAP • IL17A
    |
    pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)
    A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4) (NCT03846310)
    Phase 1
    Arcus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    04/01/2019
    Primary completion :
    08/01/2024
    Completion :
    08/01/2024
    EGFR
    |
    EGFR mutation
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Yutuo (zimberelimab) • etrumadenant (AB928)
    A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (ARC-2) (NCT03719326)
    Phase 1
    Arcus Biosciences, Inc.
    Completed
    Last update posted :
    05/24/2024
    Initiation :
    10/15/2018
    Primary completion :
    07/01/2021
    Completion :
    07/02/2021
    HER-2 • ER • PGR
    |
    HER-2 negative • ER negative • PGR negative
    |
    albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal
    Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7) (NCT04262856)
    Phase 2
    Arcus Biosciences, Inc.
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    05/28/2020
    Primary completion :
    02/01/2025
    Completion :
    02/01/2025
    PD-L1
    |
    PD-L1 expression • PD-L1 overexpression
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)
    TT-702 in Patients With Advanced Solid Tumours. (CURATE) (NCT05272709)
    Phase 1/2
    Cancer Research UK
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    01/19/2022
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    HER-2 • ER • PGR • MSI • MLH1 • MSH6 • MSH2
    |
    HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative
    |
    Nubeqa (darolutamide) • TT-702
    Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer (NCT04791839)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    04/09/2024
    Initiation :
    08/04/2021
    Primary completion :
    01/31/2025
    Completion :
    04/30/2029
    PD-L1
    |
    PD-L1 expression
    |
    Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928)
    PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer (NCT05234307)
    Phase 1
    Dwight Owen
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    11/21/2022
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    PD-L1 • ALK • STK11
    |
    Opdivo (nivolumab) • PBF-1129
    PBF-1129 in Patients With NSCLC (NCT03274479)
    Phase 1
    Palobiofarma SL
    Active, not recruiting
    Last update posted :
    02/09/2024
    Initiation :
    10/01/2018
    Primary completion :
    05/01/2024
    Completion :
    08/01/2024
    EGFR • ALK • ROS1
    |
    ALK mutation • ROS1 mutation
    |
    PBF-1129
    TT-4 as a Single Agent in Subjects With Advanced Selected Solid Tumors (NCT04976660)
    Phase 1/2
    Tarus Therapeutics, Inc.
    Not yet recruiting
    Last update posted :
    05/02/2022
    Initiation :
    12/15/2022
    Primary completion :
    06/01/2023
    Completion :
    09/30/2023
    CD4
    |
    PORT-7